The potent TGF-β antagonist Norrin as a new drug for the treatment of fibrotic diseases and cancer
Human Norrin protein has been originally identified in the art as being a crucial factor in the development of Norrie disease and is thought to be primarily involved in the Wnt signaling pathway. In the present invention, Norrin is
being identified for the first time as a potent TGF-β antagonist/inhibitor. Furthermore, it has surprisingly been found herein that Norrin can be used in the treatment of diseases associated with an increased TGF-β activity level, such as fibrotic diseases and proliferative diseases, resp. cancer.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
